XHKG1846
Market cap169mUSD
Dec 23, Last price
4.00HKD
1D
1.27%
1Q
-13.42%
IPO
-58.76%
Name
EUROEYES INTERNATIONAL EYE CLINIC LIMITED
Chart & Performance
P/E
10.06
P/S
1.85
EPS
0.40
Div Yield, %
3.00%
Shrs. gr., 5y
0.92%
Rev. gr., 5y
13.16%
Revenues
714m
+17.04%
Net income
131m
+46.68%
CFO
192m
-8.10%
Dividend
Sep 27, 20240.0349 HKD/sh
Earnings
Mar 26, 2025
Profile
EuroEyes International Eye Clinic Limited provides vision correction services in Germany, Denmark, and the People's Republic of China. The company offers refractive laser surgery, which include ReLEx SMILE and FemtoLASIK; phakic lens (ICL) surgery; lens exchange surgery comprising the monofocal and trifocal lens exchange surgery; and PRK/LASEK and ICRS implantation services. Its correction services are used for the treatment of myopia, high myopia, presbyopia, and cataract. The company serves mid-to-high income level customers, who primarily seek surgery to treat their myopia; and above 45 years of age, who primarily seek surgery to treat their presbyopia or cataract. It operates consultation centers and clinics for eye treatment and LASIK centers; and sells pharmaceutical products. The company is also involved in the trading of eye clinic equipment and lenses; and ophthalmic equipment renting and spaces operating activities. EuroEyes International Eye Clinic Limited was founded in 1993 and is headquartered in Hamburg, Germany.
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 714,289 17.04% | 610,291 -3.58% | 632,931 33.58% | |||||
Cost of revenue | 474,752 | 417,334 | 402,609 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 239,537 | 192,957 | 230,322 | |||||
NOPBT Margin | 33.54% | 31.62% | 36.39% | |||||
Operating Taxes | 57,356 | 45,462 | 63,289 | |||||
Tax Rate | 23.94% | 23.56% | 27.48% | |||||
NOPAT | 182,181 | 147,495 | 167,033 | |||||
Net income | 131,242 46.68% | 89,472 -33.01% | 133,560 103.66% | |||||
Dividends | (39,675) | (33,097) | (9,838) | |||||
Dividend yield | 2.29% | 1.81% | 0.37% | |||||
Proceeds from repurchase of equity | (9,360) | (57,976) | ||||||
BB yield | 0.51% | 2.15% | ||||||
| Debt | ||||||||
Debt current | 70,742 | 47,765 | 45,415 | |||||
Long-term debt | 696,854 | 532,774 | 392,892 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 86,213 | 78,020 | 1,042 | |||||
Net debt | 14,910 | (199,028) | (423,273) | |||||
| Cash flow | ||||||||
Cash from operating activities | 191,855 | 208,765 | 273,258 | |||||
CAPEX | (88,919) | (56,307) | (44,550) | |||||
Cash from investing activities | (180,285) | (131,814) | (59,896) | |||||
Cash from financing activities | (102,764) | (102,215) | (69,180) | |||||
FCF | 12,124 | 65,096 | 223,213 | |||||
| Balance | ||||||||
Cash | 720,384 | 779,567 | 861,580 | |||||
Long term investments | 32,302 | |||||||
Excess cash | 716,972 | 749,052 | 829,933 | |||||
Stockholders' equity | 454,249 | 394,608 | 425,519 | |||||
Invested Capital | 1,181,734 | 972,941 | 792,829 | |||||
ROIC | 16.91% | 16.71% | 20.43% | |||||
ROCE | 14.48% | 13.97% | 18.77% | |||||
| EV | ||||||||
Common stock shares outstanding | 332,247 | 332,276 | 329,156 | |||||
Price | 5.21 -5.10% | 5.49 -32.89% | 8.18 -4.10% | |||||
Market cap | 1,731,007 -5.11% | 1,824,195 -32.25% | 2,692,496 -15.97% | |||||
EV | 1,776,649 | 1,653,994 | 2,304,148 | |||||
EBITDA | 326,887 | 273,680 | 304,980 | |||||
EV/EBITDA | 5.44 | 6.04 | 7.56 | |||||
Interest | 14,144 | 7,117 | 7,491 | |||||
Interest/NOPBT | 5.90% | 3.69% | 3.25% | |||||